Company: APXIF
Filing Date: 2025-07-18
Form Type: F-4/A
Source: 0001213900-25-065703
Chunk: 640

Company: APx Acquisition Corp. I
Filing Date: 2025-07-18
Form: F-4/A
Chunk 640
---
, 2024         |     |   3,000 |     | —          |     | 4,641,019 |     |    (162,866 | ) |     | (8,263,789  | ) |     |    (3,782,636 | ) |

|                                         |     |   Share 
 capital |     |    Capital 
  inflation 
 adjustment |     |     Share 
   Premium |     |  Cumulative 
 translation 
  adjustment |   |     | Accumulated 
 deficit     |   |     |         Total 
 shareholders’ 
        equity |   |
| Balance as of June 30, 2023             |     |  13,059 |     |     39,826 |     | 3,533,699 |     |      36,113 |   |     | (3,588,427  | ) |     |        34,270 |   |
| Parent company’s contribution (Note 20) |     |       — |     |          — |     |   140,910 |     |           — |   |     | —           |   |     |       140,910 |   |
| Other comprehensive loss                |     |       — |     |          — |     |         — |     |     (11,780 | ) |     | —           |   |     |       (11,780 | ) |
| Net loss for the period                 |     |       — |     |          — |     |         — |     |           — |   |     | (1,434,684  | ) |     |    (1,434,684 | ) |
| Balance as of December 31, 2023         |     |  13,059 |     |     39,826 |     | 3,674,609 |     |      24,333 |   |     | (5,023,111  | ) |     |    (1,271,284 | ) |

The accompanying notes are an integral part of these Unaudited interim condensed Combined Financial Statements.

F-95

OmnigenicsAI Corp
Interim condensed Combined Statements of Cash Flows
For the six-month periods ended December 31, 2024 and 2023
(All amounts in US Dollars, except for share data and otherwise indicated)
(Unaudited)

|                                                                           |     | Notes |     | For the six-month